Oath Peptides Scam: The Counter-Evidence

Four independently verifiable structural records anchor the counter-evidence against the Oath Peptides scam framing. Each record is independently inspectable; each carries an identifier, an issuing body, a verification path, and a date. The question of whether Oath Peptides is legitimate resolves, not in opinion or aggregate sentiment, but in the documentary footprint that an illegitimate vendor cannot fabricate at this scale and consistency. The four records are the lab partner, the COA archive, the third-party grade, and the consistency of the testing program over time.

Three independent verification paths, none requiring trust in this site or in Oath's marketing.

Path 01 — Verify the lab. Open the CMS Clinical Laboratory Improvement Amendments database. Search for CLIA registration 14D2263999. Confirm the registered laboratory is Freedom Diagnostics, location Franklin, Tennessee. Confirm the certification is current. This is a federal database; the record is the federal government's, not Oath's.

Path 02 — Verify a COA. Open oathresearch.com's COA section. Search for a peptide by name (e.g., Tirzepatide) or by CAS number (2023788-19-2 for Tirzepatide). Open a recent COA. Confirm the issuing lab is Freedom Diagnostics. Confirm the date is recent. Confirm the purity and endotoxin status. If you have purchased Oath product and have a vial in hand, scan the vial's QR code and confirm it resolves to the same COA. This is the verification path multiple oath.reviews customers describe in their own reviews (Jeffrey H., Donna J., Devin N., Nancy I.).

Path 03 — Verify the third-party grade. Open realpeptidescores.com/vendor/oath-research. Confirm the grade is A — Recommended. Confirm the audit date. Confirm the audit identifies Freedom Diagnostics as the lab partner with CLIA registration 14D2263999. RealPeptidesScores has a published rubric; the rubric is independent of Oath. The audit is independent of this case file.

Yes. Every batch is tested by Freedom Diagnostics, an independent CLIA-certified third-party laboratory (CLIA 14D2263999, Franklin, Tennessee, verifiable in CMS's CLIA database). Not in-house. Not lot-level. Not spot-check. Batch-level coverage on 199 batches tested as of May 2026, with COAs publicly searchable on oathresearch.com by peptide name, batch number, or CAS number.

Freedom Diagnostics, an independent CLIA-certified third-party laboratory based in Franklin, Tennessee. Federal CLIA registration number 14D2263999. The relationship is a testing contract — Oath holds no ownership stake, no financial entanglement beyond verification work. CLIA certification is issued by CMS and means the lab meets federal standards for laboratory testing of human specimens, with associated oversight, inspection, and proficiency testing. The lab serves multiple unrelated peptide vendors per the independent RealPeptidesScores audit.

The COAs are issued by an independent third-party lab (Freedom Diagnostics, not Oath itself), are publicly archived at oathresearch.com (no paywall, no login required), and identify the batch number, test date, methodology, purity result, and endotoxin pass/fail status under USP <85>. The structure is what enables verification — anyone can search the archive by peptide name, batch number, or CAS number, and audit the result independently. Multiple oath.reviews customers describe their verification workflow in their own reviews: scanning the QR code on a shipped vial and confirming the COA resolves to the matching lot. The customer-funded independent retest by Nancy I. (Tirzepatide, 2026-05-23) — see the dedicated callout at the top of this page — confirms the posted COA against an independent third-party laboratory analysis.

199 batches as of May 2026, with the program actively growing. The full archive is publicly searchable in the COA section of oathresearch.com. The RealPeptidesScores audit lists 142 of those 199 batches in its own database — roughly 29% incomplete relative to Oath's full record — and still assigns Grade A on the partial view. A scam vendor does not maintain a 199-batch independent-lab-verified public COA archive, with batch-level traceable QR codes, an audit by an independent third-party reviewer rating the program at the top tier, and a customer-funded independent retest matching the posted COA.

99.60% average purity across the publicly archived batches. Per-compound highlights from the verified record: SS-31 at 99.86% across 4 batches, GLP2-T (Tirzepatide) at 99.93% across 8 batches, BPC-157 at 99.66% across 10 batches, Selank at 99.71% across 5 batches, the BPC-157 + TB-500 (WOLVERINE) blend at 99.39% across 8 batches, and the Tesamorelin + Ipamorelin blend at 99.43% across 6 batches. The blend coverage is editorially worth pointing out: blended formulations are batch-tested at the same coverage tier as monomers, which is not always the industry standard.

Yes. The listing is at realpeptidescores.com/vendor/oath-research. Grade: A — Recommended. Audit date: 2026-05-09. The audit names Freedom Diagnostics as the lab partner with CLIA registration 14D2263999 and confirms batch-level COA coverage, named-lab verifiability, portal verification capability, recency within 90 days, branded vials in PDFs, and an annual COA volume well above the rubric's minimum threshold. RealPeptidesScores is a human-reviewed scoring service with a published rubric — distinct from pay-to-rate services like peptidescore.com and from algorithmic scanners like ScamAdviser. The listing shows 142 of Oath's 199 actual batches, an incomplete view, and still awards Grade A.

Three paths, none requiring trust in this site: (1) Verify the lab — search CMS's CLIA database for registration 14D2263999, confirming Freedom Diagnostics' federal certification; (2) Verify a COA — search Oath's public COA archive at oathresearch.com by peptide name, batch number, or CAS number, and inspect the issuing lab on a specific recent certificate; (3) Verify the third-party grade — read the RealPeptidesScores audit at realpeptidescores.com/vendor/oath-research, examine the rubric, and check the published cross-batch verifications. Each path is independent of the other two. Each path resolves to a record issued by an organization not under Oath's control.

The verified subset visible in the publicly archived COA record includes SS-31 (CAS 736992-21-5), BPC-157 (CAS 137525-51-0), Selank (CAS 129954-34-3), GLP2-T (Tirzepatide) (CAS 2023788-19-2), and GLP3-R (Retatrutide) (CAS 2381089-83-2), plus blended formulations including BPC-157 + TB-500 (WOLVERINE) and Tesamorelin + Ipamorelin. The catalog also includes additional blends — BPC-157 + TB-500 + GHK-Cu, and BPC-157 + TB-500 + GHK-Cu + KPV — visible in the snapshot. The published catalog is larger than this verified subset; the openpr press release of 2025-12-22 confirms the complete GLP-1 lineup (semaglutide, tirzepatide, retatrutide), placing all three GLP-1 products peptidescore.com accused inside Oath's published catalog and inside the COA-verified record.

USP <85> is the United States Pharmacopeia standard for bacterial endotoxin testing — a pharmaceutical-grade method for detecting lipopolysaccharide contamination that could cause adverse reactions in an injectable formulation. Purity describes whether the molecule in the vial is what it claims to be; endotoxin testing describes whether the contents are safe to handle in an injectable preparation, independent of identity. Every visible COA in Oath's archive carries an ENDO PASSED notation under this standard. The combination — high HPLC purity plus USP <85> endotoxin pass — is the pharmaceutical-grade two-axis safety floor that a research-peptide vendor with a credible testing program ships against.

Real red flags in this category include: no third-party lab testing (in-house only or none); no published COAs, or COAs that cannot be verified back to an issuing lab; unverifiable lab partnerships (lab names that do not appear in any federal database, or that appear but with no active certification); FDA-approval claims for research peptides (which are not FDA-approved as a category — a vendor claiming FDA approval is making an unsupportable claim); invented credentials or fabricated certifications; no published business address or operator information; and pricing far below realistic synthesis cost. Oath does not exhibit any of these red flags. The lab partner is CLIA-verifiable. The COAs are publicly searchable. Oath does not claim FDA approval. The published business address — 51 West Vaughn Ave Suite 205, Gilbert AZ 85233 — is corroborated by three independent business directories and by customer reviewers mentioning Arizona shipping origin.